Arbutus Biopharma Corp Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount
Arbutus Biopharma Corp (ABUS) reported Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-04.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate · last filed 2021-03-04
CAD
| Period end | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount 12 month |
|---|---|
| 2012-12-31 | 777.00K CAD 20-F · filed 2013-03-27 |
| 2011-12-31 | 712.24K CAD 20-F · filed 2013-03-27 |
USD
| Period end | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount 12 month | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount 12 month as first filed |
|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-04 | |
| 2019-12-31 | $8.36M 10-K · filed 2021-03-04 | |
| 2018-12-31 | $0.00 10-K · filed 2020-03-05 | |
| 2017-12-31 | -$6.63M 10-K · filed 2019-03-07 | |
| 2016-12-31 | $0.00 10-K · filed 2018-03-16 | |
| 2015-12-31 | $0.00 10-K · filed 2018-03-16 | |
| 2014-12-31 | $0.00 10-K · filed 2016-03-09 | |
| 2013-12-31 | -$9.00K 10-K · filed 2016-03-09 | -$5.72K 6-K · filed 2014-03-06 |
| 2012-12-31 | $781.00 10-K · filed 2015-03-13 | $780.96K 6-K · filed 2014-03-06 |
| 2011-12-31 | $700.34K 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |